Patients with cancer are surviving longer and are at increasingly higher risk for developing cardiovascular disease, which threatens to undermine cancer outcomes by adversely affecting short-and long-term morbidity and mortality. Accordingly, the cardio-oncology field has emerged to address the cardiovascular consequences of cancer and cancer therapies by promoting awareness of cardiovascular risk factors and care needs of patients with cancer, 1 and by collaboration among oncologists and cardiologists aimed at mitigating cardiovascular morbidity and mortality while avoiding unnecessary discontinuation of essential anticancer therapy or overtreatment of individuals not at risk. 2 Thus far, a major focus in cardio-oncology has been on the myocardial toxicities of conventional and novel anticancer agents associated with an increased risk of cardiomyopathy and symptomatic heart failure.
by collaboration among oncologists and cardiologists aimed at mitigating cardiovascular morbidity and mortality while avoiding unnecessary discontinuation of essential anticancer therapy or overtreatment of individuals not at risk. 2 Thus far, a major focus in cardio-oncology has been on the myocardial toxicities of conventional and novel anticancer agents associated with an increased risk of cardiomyopathy and symptomatic heart failure. 2 The potential adverse metabolic effects of various cancer therapies and their contribution to cardiovascular injury and disease have received comparatively less attention. In the accompanying clinical review, Gupta et al 3 have addressed the underappreciated cardiometabolic toxicities of androgen-deprivation therapy (ADT), including novel agents, in prostate cancer. Conventional ADT that results in lowering total serum testosterone to less than 50 ng/dL is the mainstay of treatment for advanced prostate cancer with about 600,000 men in the United States currently receiving ADT. 4 However, despite demonstrated efficacy, conventional ADT causes multiple detrimental metabolic and physical adverse effects, including muscle wasting (atrophy), decreased lean body mass (sarcopenia), increased body fat mass (obesity), and increased insulin resistance, which lead to a 44% increased risk of new onset type 2 diabetes and 16% risk of new ischemic heart disease. 5, 8 As Gupta et al describe in their review, novel ADT agents (ie, enzalutamide, abiraterone, and apalutamide) may exacerbate these adverse effects.
We believe these cardiometabolic toxicities are actually low-hanging fruit that may be monitored easily by using simple, readily available elements of the history (Do you smoke? Do you exercise?), physical examination (body mass index, blood pressure), and blood biomarkers that are ubiquitous and well-accepted surrogate risk markers for coronary heart disease (lipid profile, fasting glucose, or hemoglobin A1c). 9 By comparison, strategies for stratifying risk for cancer therapy-related cardiomyopathy use advanced cardiac imaging modalities and blood-based biomarkers that are more complex and have a less wellestablished evidence base to support diagnostic and prognostic utility, reproducibility, and treatment thresholds. 10 The approach summarized by Gupta et al 3 suggests an opportunity to translate well-accepted assessments (ie, low-density lipoprotein, hemoglobin A1c) for the cardiometabolic risk of ADT into an effective model for cardio-oncologic care. Such a model would incorporate established cardiovascular risk calculators to facilitate clear criteria for cardiology referral and intervention. Improving care delivery also presents an opportunity to pick the low-hanging fruit. Currently, ADT may be administered by urologists, or the patient may transition to the care of a medical or radiation oncologist. The different backgrounds of physicians who administer ADT predisposes to a heterogeneous approach because not all physicians are similarly trained, habituated, or incentivized to provide cardiometabolic screening or monitoring. For instance, patients often complain of hot flashes, fatigue, or decreased libido after starting ADT, but cardiometabolic adverse effects are often more insidious and may go unnoticed unless the appropriate assessments are ordered. Moreover, a patient's other physicians (eg, primary care provider or cardiologist) may not consider cardiometabolic toxicity because they are unaware that conventional ADT with gonadotropin-releasing hormone (GnRH) agonists and antagonists via injection are being administered elsewhere or because they are unfamiliar with recently approved novel agents.
Better multidisciplinary collaboration provides a potential solution. Not all patients have access to an integrated cardiooncology clinic. However, electronic medical records (EMRs) can facilitate communication among urologists, oncologists, primarycare providers,and cardiologists. Moreover,evidencebased guidelines that address cardiometabolic toxicities could be incorporated into EMRs to provide clinical guidance. Innovative solutions should also be sought. For instance, the Movember Foundation has funded a trial, A Survivorship Care Plan and Embedded Navigation Tool (ASCENT; ClinicalTrials.gov identifier: NCT03424837) that is examining an online tool to facilitate communication among patients and their providers aimed at maximizing adherence to the American Cancer Society Prostate Cancer Survivorship Care Guidelines.
Cardiovascular interventions (summarized in Awareness is fundamental to mitigating cardiometabolic risks. Treating diabetes, hypertension, and hyperlipidemia; counseling for smoking cessation; and promoting healthy lifestyle behaviors is no different in men with prostate cancer than in patients without cancer. However, providers must first recognize the increased risks posed by ADT so they can collaborate to prevent or at least treat the cardiometabolic toxicities (Fig 1) . Or, as Sophocles said, "Look and you will find it-what is unsought will go undetected."
